The Biology Behind BCL2 as a Target in Myeloma

Slides:

Advertisements

Similar presentations

When mammalian cells are subjected to stress signals, oxygen deficiency, radiation, DNA damage, or Chemo- therapeutic drugs, p53 is activated, leading.

Advertisements

Activation of T Lymphocytes

PI3K inhibition does not Effect the BH3 Profile of SW620 Cells

Reeder CB et al. ASCO 2009; Abstract (Poster)

Control of Gene Expression

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Introduction/Background

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Dry AMD and GA: The Present and Future

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

HUWE1 inhibition as a therapeutic strategy to target MYC in MM

Overall Program Goals. Overall Program Goals Current Approaches.

The Genomics of Cancer and Molecular Testing:

New Directions in iTTP.

Metastatic Renal Cell Carcinoma

Cancer Stem Cell Therapies in Gastrointestinal Cancers

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Activity Goals. Activity Goals Discussion Topics.

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

B lymphocytes produce antibodies.

Challenges in Managing Progressive Multiple Sclerosis

Novel and Emerging Approaches to Treating CLL

Assessing Disease Progression in MS Treatment

Updates in Lymphoma From Recent Congresses

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Multiple Myeloma

EHL Technologies in Hemophilia Care

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Mutational Testing to Select Novel Targeted Therapies in AML

Advancing the Treatment of IBD With Biologics

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

The Evolving Treatment Landscape in Atopic Dermatitis

Program Goals Overview Is NEDA a Reasonable Target?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

What's New in Therapeutic Options for Moderate to Severe RA?

Apoptosis, Up the Ante Cancer Cell

Advancing Patient Care in RA

Apoptosis-targeted therapies for cancer

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Proteasome Inhibitors and Patients

On the Cusp: New Approaches for Multiple Myeloma

AML Therapy: Wake Up the Guardian and Cut Loose the Executioners

Clinical Challenges and Updates in Managing Seizure Clusters

Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells Nabanita Mukherjee, Josianna V. Schwan, Mayumi.

Death receptor-mediated apoptosis and the liver

Renal Function and Myeloma Therapeutics

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Apoptosis-targeted therapies for cancer

AMD Therapy: Where Are We Now and Where Are We Going?

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Targeting Apoptosis in AML

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Understanding Apoptotic Mechanisms

Autoimmune Disease and miRNAs

János Fekete, Balázs Győrffy

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Venetoclax acts through on-target BCL2 inhibition.

What's New in Rare CKDs?.

Apoptosis: Activate NF-κB or die?

A New Era in Migraine Prevention

Presentation transcript:

The Biology Behind BCL2 as a Target in Myeloma

Apoptosis

BCL2 Family of Proteins

Apoptotic Pathways

Apoptosis Initiation

Mechanisms of BCL2 Family Dysregulation

Patterns of Expression of Key BCL2-Family Proteins in Patients With Multiple Myeloma

Cytokines Regulate Expression of BCL2-Family Proteins BCL2, BCLXL, and MCL1

BCL2 as a Therapeutic Target

Venetoclax

Mechanisms of Resistance

Combining Anti-BCL2 Therapy with Dexamethasone

Predicting Sensitivity to Anti-BCL2 Therapy

Myeloma, t(11;14), and BCL2

Bcl2 Inhibition and t(11;14)

Venetoclax Phase 1 in RRMM: Design

Venetoclax Phase 1 in RRMM: Key Patient Characteristics

Venetoclax Phase 1 in RRMM: Safety

Venetoclax Phase 1 in RRMM: Response

Venetoclax Phase 1 in RRMM: TTP and DOR

Venetoclax in Phase 1 in RRMM: BCL2: BCL2L1 Ratio

Venetoclax Phase 1 in RRMM: Responses by BCL2:BCL2L1 Ratio Among t(11;14)-Positive Patients

Enhancing the BCL2 Inhibition Strategy

Venetoclax and Bortezomib: Background

Venetoclax + Bortezomib Phase 1 in RRMM: Design

Venetoclax + Bortezomib Phase 1 in RRMM: Key Patient Characteristics

Venetoclax + Bortezomib Phase 1 in RRMM: Safety

Venetoclax + Bortezomib Phase 1 in RRMM: Response

Venetoclax + Bortezomib Phase 1 in RRMM: Response By Lines of Therapy

Venetoclax + Bortezomib Phase 1 in RRMM: TTP and DOR

Venetoclax + Bortezomib Phase 1 in RRMM: BCL2 Gene Expression and Clinical Response

Enhancing the Bcl2 Inhibition Strategy

Ongoing Evaluation of Anti-BCL2 Therapy in Patients with Multiple Myeloma

Developing Biomarkers to Predict Response to Anti-BCL2 Therapy

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)